Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation

• DOI: 10.1016/j.ijrobp.2017.01.020
• Publication Date: 2017-01-12T19:48:09Z
• Authors: Asal Rahimi; Kimberly Thomas; Ann Spangler; Roshni Rao; Marilyn Leitch; Rachel Wooldridge; Aeisha Rivers; Stephen Seiler; Kevin Albuquerque; Stella Stevenson; Sally Goudreau; Dan Garwood; Barbara Haley; David Euhus; John Heinzerling; Chuxiong Ding; Ang Gao; Chul Ahn; Robert Timmerman
• Keywords: Carcinoma, Ductal, Breast; Breast Neoplasms; Middle Aged; Mastectomy, Segmental; Radiosurgery; Radiation Tolerance; Tumor Burden; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Fiducial Markers; Feasibility Studies; Humans; Female; Radiotherapy, Adjuvant; Dose Fractionation, Radiation; Prospective Studies; Breast Carcinoma In Situ; Aged

To evaluate the tolerability of a dose-escalated 5-fraction stereotactic body radiation therapy for partial-breast irradiation (S-PBI) in treating early-stage breast cancer after partial mastectomy; the primary objective was to escalate dose utilizing a robotic stereotactic radiation system treating the lumpectomy cavity without exceeding the maximum tolerated dose.Eligible patients included those with ductal carcinoma in situ or invasive nonlobular epithelial histologies and stage 0, I, or II, with tumor size <3 cm. Patients and physicians completed baseline and subsequent cosmesis outcome questionnaires. Starting dose was 30 Gy in 5 fractions and was escalated by 2.5 Gy total for each cohort to 40 Gy.In all, 75 patients were enrolled, with a median age of 62 years. Median follow-up for 5 cohorts was 49.9, 42.5, 25.7, 20.3, and 13.5 months, respectively. Only 3 grade 3 toxicities were experienced. There was 1 dose-limiting toxicity in the overall cohort. Ten patients experienced palpable fat necrosis (4 of which were symptomatic). Physicians scored cosmesis as excellent or good in 95.9%, 100%, 96.7%, and 100% at baseline and 6, 12, and 24 months after S-PBI, whereas patients scored the same periods as 86.5%, 97.1%, 95.1%, and 95.3%, respectively. The disagreement rates between MDs and patients during those periods were 9.4%, 2.9%, 1.6%, and 4.7%, respectively. There have been no recurrences or distant metastases.Dose was escalated to the target dose of 40 Gy in 5 fractions, with the occurrence of only 1 dose-limiting toxicity. Patients felt cosmetic results improved within the first year after surgery and stereotactic body radiation therapy. Our results show minimal toxicity with excellent cosmesis; however, further follow-up is warranted in future studies. This study is the first to show the safety, tolerability, feasibility, and cosmesis results of a 5-fraction dose-escalated S-PBI treatment for early-stage breast cancer in the adjuvant setting.